Thrombin-cleaved osteopontin is increased in urine of patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 37, Issue 4, 2010, Pages 704-710

  Shio, Kiori ^a   Kobayashi, Hiroko ^a   Asano, Tomoyuki ^a   Saito, Rie ^a   Iwadate, Haruyo ^a   Watanabe, Hiroshi ^a   Sakuma, Hirofumi ^b   Segawa, Tetsuya ^c   Maeda, Masahiro ^c   Ohira, Hiromasa ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b Saiseikai Kawamata Hospital   (Japan)

^c Immuno Biological Laboratories Co Ltd   (Japan)

Author keywords

Osteopontin; Rheumatoid arthritis; Thrombin

Indexed keywords

C REACTIVE PROTEIN; OSTEOPONTIN; RHEUMATOID FACTOR; STROMELYSIN; THROMBIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOARTHRITIS; OSTEOPONTIN; PAIN MEASUREMENT; PROTEIN ISOFORMS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; THROMBIN;

EID: 77950640465     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090582     Document Type: Article

References (25)

1. Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem 1987;262:2900-2907
2. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-864 (Pubitemid 30084330)
3. Gravallese EM. Osteopontin: a bridge between bone and the immune system. J Clin Invest 2003;112:147-149
4. Petrow PK, Hummel KM, Schedel J, Franz JK, Klein CL, Muller-Ladner U, et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000;43:1597-1605 (Pubitemid 30452481)
5. Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002;29:2061-2067
6. Xu G, Sun W, He D, Wang L, Zheng W, Nie H, et al. Overexpression of osteopontin in rheumatoid synovial mononuclear cells is associated with joint inflammation, not with genetic polymorphism. J Rheumatol 2005;32:410-416 (Pubitemid 40381409)
7. Xu G, Nie H, Li N, Zheng W, Zhang D, Feng G, et al. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 2005;115:1060-1067 (Pubitemid 40489411)
8. Ohshima S, Kobayashi H, Yamaguchi N, et al. Expression of osteopontin at sites of bone erosion in a murine experimental arthritis model of collagen-induced arthritis: possible involvement of osteopontin in bone destruction in arthritis. Arthritis Rheum 2002;46:1094-1101 (Pubitemid 34303824)
9. Sennels HP, Sorensen S, Ostergaard M, Knudsen L, Hansen M, Skjodt H, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. Scand J Rheumatol 2008;37:241-247 (Pubitemid 351962322)
10. Hasegawa M, Nakoshi Y, Irino T, Sudo A, Segawa T, Maeda M, et al. Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol 2009;36:240-245
11. Ohba T, Takase Y, Ohhara M, Kasukawa R. Thrombin in the synovial fluid of patients with rheumatoid arthritis mediates proliferation of synovial fibroblast-like cells by induction of platelet derived growth factor. J Rheumatol 1996;23:1505-1511 (Pubitemid 26290573)
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324
13. Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
14. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-662
15. Hochberg MC, Chang RW, Dwosh I, Lindsey S, Pincus T, Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
16. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000;77:487-498 (Pubitemid 30230602)
17. Min W, Shiraga H, Chalko C, Goldfarb S, Krishna GG, Hoyer JR. Quantitative studies of human urinary excretion of uropontin. Kidney Int 1998;53:189-193 (Pubitemid 28066920)
18. Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002;46:906-912 (Pubitemid 34303801)
19. Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TPM, Van Zeben D, Vos K, Breedveld FC, et al. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year follow up. Arthritis Rheum 2002;47:383-390
20. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-858
21. Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani H, et al. Elevation of serum matrix metalloproteinase 3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol 2007;17:403-408 (Pubitemid 47593489)
22. Attur MG, Dave MN, Stuchin S, Kowalski AJ, Steiner G, Abramson SB, et al. Osteopontin. An intrinsic inhibitor of inflammation in cartilage. Arthritis Rheum 2001;44:578-584
23. Yamamoto N, Sakai F, Kon S, Morimoto J, Kimura C, Yamazaki H, et al. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest 2003;112:181-188 (Pubitemid 38056354)
24. Fan K, Dai J, Wang H, Wei H, Cao Z, Hou S, et al. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum 2008;58:2041-2052 (Pubitemid 351988096)
25. Du J, Hou S, Zhong C, Lai Z, Yang H, Dai J, et al. Molecular basis of recognition of human osteopontin by 23C3, a potential therapeutic antibody for treatment of rheumatoid arthritis. J Mol Biol 2008;382:835-842